AZD1222 COVID-19 Vaccine Shows 100% Efficacy Against Severe Disease with No Hospitalizations in Phase III Trial Published in The Lancet
AstraZeneca
Biopharmaceutical Manufacturer
University of Oxford
The University of Oxford (commonly referred to as "Oxford") is a public research university located in Oxford, England. Operating under a collegiate federal system, it is collectively known with the University of Cambridge as "Oxbridge." Together with the University of Cambridge, University College London, Imperial College London, and the London School of Economics and Political Science, it forms the "G5 Super Elite Universities."While the exact founding date of the University of Oxford is lost to history, archival records clearly indicate that teaching commenced as early as 1096. The university experienced rapid development after receiving substantial support from the English royal family in 1167. It is the oldest university in the English-speaking world and the second-oldest surviving higher education institution globally. The University of Oxford holds prestigious academic standing and extensive influence in fields such as mathematics, physics, medicine, law, and business, and is widely recognized as one of the world’s leading higher education institutions. In the 2017–18 Times Higher Education World University Rankings, Oxford ranked first worldwide; in the Academic Ranking of World Universities (ARWU), it ranked seventh globally.On December 18, 2018, the "2018 World Brand 500" list, compiled by the World Brand Lab, was released, with the University of Oxford ranked 99th.
Today, AstraZeneca announced that the interim analysis results of the Phase 3 clinical program for the candidate COVID-19 vaccine AZD1222, conducted by the University of Oxford, have been peer-reviewed and published in The Lancet. Based on data from 131 symptomatic COVID-19 cases accumulated among 11,636 participants, the analysis demonstrated that the vaccine is safe and effective in preventing symptomatic COVID-19 and can prevent severe disease and hospitalization.
Analysis of the efficacy in preventing symptomatic COVID-19 showed that vaccine efficacy was 62.1% (n=8,895; CI 41.0%-75.7%) when administered as two full doses, and 90.0% (n=2,741; CI 67.4%-97.0%) in subjects who received a half dose followed by a full dose.
In the prevention of severe COVID-19, no hospitalizations or severe cases of COVID-19 were observed in the vaccine group 21 days after the first dose. In the control group, 10 participants were hospitalized due to COVID-19, among whom 2 were assessed as severe cases, including 1 fatal case.
In terms of safety, the currently accumulated safety data are derived from over 20,000 participants in four clinical trials conducted in the United Kingdom, Brazil, and South Africa. AZD1222 demonstrated a favorable safety and tolerability profile, with rates of serious adverse events reported at 0.7% in the vaccine group and 0.8% in the control group. No vaccine-related serious adverse events were identified in the vaccine group.
References:
[1] Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalisations more than 21 days after first injection. Retrieved December 8, 2020, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet.html
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.▽Follow [WuXi AppTecDe】WeChat Official Account
